GlassScriptPhysician profile
Samantha M Smith
NPI 1972003184
$1,040.31
in general payments reported to CMS, 2019-2025
22 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.77 · 2023: $160 · 2024: $339 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $273.36 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $119.50 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.90 | 2023-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $76.05 | 2025 | Bexsero, Penmenvy, Pediarix |
| Vanda Pharmaceuticals INC. | $46.06 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $45.37 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $42.95 | 2024-2025 | Keveyis |
| Abbvie INC. | $42.35 | 2023-2024 | |
| Astellas Pharma US INC | $41.86 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $28.37 | 2024-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Seqirus USA INC | $26.87 | 2025 | Flucelvax, Fluad |
| Ardelyx, INC. | $24.66 | 2025 | Ibsrela |
| Ibsa Pharma INC. | $22.85 | 2024 | Licart, Tirosint |
| Exact Sciences Corporation | $18.73 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $18.35 | 2024 | Minimed 780g |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.05 | 2025 | Caplyta |
| Amgen INC. | $16.86 | 2023 | Repatha, Otezla |
| Dexcom, INC. | $16.69 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $16.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.30 | 2024 | Ofev |
| Novartis Pharmaceuticals Corporation | $15.45 | 2021 | |
| Sanofi Pasteur INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.